Get access to our best features

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Summary by Ground News
Verve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.
Published 3 months ago

News Articles

More Filters
All
Left
Center
Right

FDA places clinical hold on Verve Therapeutics gene-editing treatment

The therapy, VERVE-101, uses a form of CRISPR to treat familial hypercholesterolemia, a relatively common form of high cholesterol.

3 months ago
Read Full Article

FDA Places Clinical Hold on Verve's Cardio Base Editing Therapy

FDA places clinical hold on Verve Therapeutics' IND application for lead candidate VERVE-101 for Heterozygous Familial Hypercholesterolemia.

3 months ago
Read Full Article

Similar News Topics

Show All
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
STAT
C 100%
See less detail